The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

In Brief

SRI International awarded contract for NCI PREVENT program

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

SRI INTERNATIONAL was awarded a contract of up to $9 million to provide preclinical development services to the NCI PREVENT Cancer Program.

Under the contract, SRI will provide scientific expertise, modern testing and support facilities, and analytical instrumentation to conduct a wide variety of preclinical pharmacology and toxicology studies to evaluate potential cancer prevention drugs.

The PREVENT Cancer Drug Development Program is an NCI-supported pipeline to bring new cancer preventing interventions and biomarkers through preclinical development towards clinical trials. PREVENT enables milestone-driven progression of novel cancer preventive chemical or biological agents and biomarkers from the laboratory bench towards proof-of-principle clinical testing and registration or validation.

The current contract calls for SRI to deliver high-quality laboratory data to support NCI-PCP’s efforts to develop promising therapeutic candidates such as vaccines and cancer chemopreventive agents that will inhibit, delay or reverse manifestations of cancer. SRI will be responsible for managing therapeutic candidates from conception to submission of an Investigational New Drug application to FDA.

Table of Contents

YOU MAY BE INTERESTED IN

News Analysis

GRAIL presses on with Galleri test despite missed primary endpoint in pivotal study
Where GRAIL sees signals of benefit in the subgroups, screening experts see signs of overdiagnosis

If you listen to GRAIL executives discuss the results of the long-awaited trial of the company’s multicancer detection test, you might be led to conclude that the company’s pivotal NHS-Galleri study had an overwhelmingly positive result.
By Jacquelyn Cobb and Sara Willa Ernst
Conversation with The Cancer Letter

GRAIL’s Megan Hall: “I think we can be confident that there is clinical benefit to implementing this technology. And I think that’s really hard to argue with.”
Mainstream epidemiologists beg to differ

Undeterred by the negative topline result of its pivotal trial of Galleri, a multicancer detection test, the test’s sponsor, GRAIL, said it’s forging ahead with its plan to get FDA approval and reimbursement from CMS and private insurers.
By Jacquelyn Cobb and Sara Willa Ernst
Conversation with The Cancer Letter

NCI’s Philip Castle on NHS-Galleri results: “I’m sorry that it didn’t work, but it keeps the national conversation going.”
Castle is “disappointed” by Galleri results but not discouraged by implications for MCDs

Philip E. Castle, director of the NCI Division of Cancer Prevention, said he was disappointed to hear that GRAIL’s NHS-Galleri trial did not meet its primary endpoint of reduction in late-stage cancers.
By Jacquelyn Cobb and Sara Willa Ernst
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account